• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

US - CDC HAN Health Update: Diagnostic Testing of Urine Specimens for Suspected Zika Virus Infection - May 25, 2016

sharon sanders

sharon sanders

Editor-in-Chief & President
https://content.govdelivery.com/accounts/USCDC/bulletins/14b7d74

From: Centers for Disease Control & Prevention <cdc@service..
To: flutrackers@earthlink.net
Subject: CDC Health Alert Network (HAN) Health Advisory Regarding HAN Diagnostic Testing of Urine Specimens for Suspected Zika Virus Infection
Date: May 25, 2016 4:32 PM

[TABLE="class: msgbody, border: 0, cellpadding: 0, cellspacing: 0"]
[TR]
[TD] [TABLE="align: center, border: 0, cellpadding: 0, cellspacing: 0"]
[TR]
[TD] Having trouble viewing this email? View it as a Web page.

[TABLE="align: center, border: 0, width: 680"]
[TR]
[TD] The following CDC Health Alert Network (HAN) Health Advisory message was issued February 23, 2016. You are receiving this information because you subscribe to COCA email updates. If a colleague forwarded this email to you, yet you would like to receive future updates directly from COCA, click here.
If you have any questions on this or other clinical issues, please e-mail coca@cdc.gov
On behalf of the Clinician Outreach and Communication Activity (COCA)
Centers for Disease Control and Prevention (CDC)
Join us on Facebook
[/TD]
[/TR]
[TR]
[TD]
Please note: HAN category has been corrected to Health Update.
This is an official
CDC HEALTH UPDATE​
Distributed via the CDC Health Alert Network
May 25, 2016, 14:15 EST (2:15 PM EST)
CDCHAN-00389
[h=1]Diagnostic Testing of Urine Specimens for
Suspected Zika Virus Infection[/h] Summary
On May 13, 2016, the Centers for Disease Control and Prevention (CDC) issued interim guidance(http://www.cdc.gov/mmwr/volumes/65/wr/mm6518e1.htm) that recommends Zika virus rRT-PCR testing of urine collected less than 14 days after symptom onset, along with testing of patient-matched serum samples, for the diagnosis of suspected Zika virus infection (1). The purpose of this Health Alert Network (HAN) health update is to further disseminate information about the interim guidance to clinical and public health professionals.
Background
Zika virus is a mosquito-borne flavivirus. Zika virus infection during pregnancy can cause microcephaly and other severe fetal brain defects. Zika virus infection is also associated with Guillain-Barr? syndrome. Transmission of Zika can occur through mosquito bite, from a pregnant woman to her fetus, through sexual contact with an infected male, and possibly through blood transfusion. The most common symptoms of Zika virus disease are fever, rash, joint pain, or conjunctivitis. Other common symptoms include muscle pain and headache. Evidence from case reports and experience from related flavivirus infections indicate that the incubation period for Zika is likely a few to 14 days.
Diagnostic testing for Zika virus infection can be accomplished using molecular and serologic methods. The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) (http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm) for several diagnostic assays to detect Zika virus infection (2). The EUAs authorize real-time reverse transcription-polymerase chain reaction (rRT-PCR) assays to detect Zika virus RNA in specified clinical sample types, and an immunoglobulin M (IgM) antibody capture enzyme-linked immunosorbent assay (ELISA) to detect anti-Zika virus IgM antibodies in serum and cerebrospinal fluid. The CDC Trioplex rRT-PCR assay is authorized by FDA for Zika virus testing of urine and serum. Anti-Zika IgM antibodies develop during the first week of illness and persist for approximately 12 weeks following infection. However, extensive cross-reactivity can occur in flavivirus serological assays, and therefore additional tests, such as the plaque reduction neutralization test (PRNT), are necessary to distinguish Zika virus infection from other flavivirus infections.
CDC recommendations for Zika virus testing of serum and other clinical specimens remain unchanged at this time. Please contact your state or local health department to facilitate testing.
Recommendations for Health Care Providers and Public Health Practitioners
  • Collect urine samples within 14 days post symptom onset along with patient-matched serum samples for those who match CDC Zika virus clinical and/or epidemiological testing criteria for Zika virus infection.
  • Perform Zika virus rRT-PCR testing on urine, in conjunction with testing of serum using the appropriate molecular or serologic assay, based on days post symptom onset.
Additional Considerations
  • Further investigation is needed to determine the sensitivity and utility of Zika virus rRT-PCR on urine specimens collected ≥14 days after onset of symptoms: limited data in pregnant women suggest that viremia in serum might be prolonged in pregnancy (4, 5).
References
  • CDC. Interim guidance for Zika virus testing of Urine ? United States, 2016.MMWR Morb Mortal Wkly Rep 2016; 65. DOI: http://dx.doi.org/10.15585/mmwr.mm6518e1.
  • Food and Drug Administration. Emergency Use Authorizations.http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm
  • Comparison of Test Results for Zika Virus RNA in Urine, Serum, and Saliva Specimens from Persons with Travel-Associated Zika Virus Disease ? Florida, 2016http://www.cdc.gov/mmwr/volumes/65/wr/mm6518e2.htm
  • Driggers RW, Ho CY, Korhonen EM, et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N Engl J Med. March 30, 2016. DOI: 10.1056/NEJMoa1601824
  • Bocanegra C. Zika virus infection in pregnant women in Barcelona, Spain. Clin Microbiol Infect. April 3, 2016. DOI: 10.1016/j.cmi.2016.03.025.
For More Information
[/TD]
[/TR]
[TR]
[TD]

DEPARTMENT OF HEALTH AND HUMAN SERVICES​
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.​
​

[/TD]
[/TR]
[TR]
[TD]
Categories of Health Alert Network messages:
Health Alert Requires immediate action or attention; highest level of importance
Health Advisory May not require immediate action; provides important information for a specific incident or situation
Health Update Unlikely to require immediate action; provides updated information regarding an incident or situation
HAN Info Service Does not require immediate action; provides general public health information
[/TD]
[/TR]
[/TABLE]
[/TD]
[/TR]
[/TABLE]
[/TD]
[/TR]
[/TABLE]
 
You must log in or register to reply here.
Back
Top Bottom